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Abstract: Prescription medicines aim to relieve patients’ suffering but they can be associated
with adverse side effects or adverse drug reactions (ADRs). ADRs are an important cause of
hospital admissions and a financial burden on healthcare systems across the globe. There is little
integrative and collective knowledge on ADR reporting and monitoring in the Norwegian healthcare
system. Accordingly, this systematic review aims to investigate the current trends in ADR reporting,
monitoring, and handling in the Norwegian healthcare system and describe related interventions.
Appropriate keywords, with regard to ADRs in both English and Norwegian languages, were used
to retrieve articles published from 2010 to 2019. Six articles met the inclusion criteria. The findings
offer a comprehensive picture of ADR reporting and monitoring in the Norwegian healthcare system.
Psychotropic medicines were most commonly implicated by patients, while professionals most
commonly reported ADRs associated with anticoagulants. The current ADR systems were compiled
with the involvement of both patients and healthcare providers to record all types of drugs and ADRs
of various severities, and aimed at improving ADR tracking. However, there is a need to improve
current initiatives in terms of feedback and quality, and more studies are needed to explore how ADR
profiles, and the associated vigilance, can improve the safety of medicines management in Norway.
Keywords: adverse drug reactions; patient safety; nursing; medicines management; healthcare
provider; ADR
1. Introduction
The prescription and administration of medicines aims to relieve patients’ suffering and ailments.
However, they can be associated with adverse side effects or adverse drug reactions (ADRs) that lead
to physical and psychological harm, much of which can be prevented. An ADR is defined by the
World Health Organization (WHO) as an unintended reaction in the patient to a medicine associated
with any dose administered by the healthcare provider [1]. Serious ADRs are those that can result in
life-threatening conditions, persistent or significant disability, prolonged hospitalization, congenital
anomalies or death [2]. Efforts have been made world-wide to reduce the number of preventable
ADRs [3–5]. ADRs cause 5–8% of unplanned hospital admissions in the UK and cost £2.5 billion
each year [6,7]. Many patients benefit from prescribed medicines [8], but the high prevalence of
ADRs (7.2–8.4%) in community or ambulatory care settings is a challenge to successful medicines
management and patient safety strategies [9].
ADRs are an ever increasing and substantial burden on healthcare systems and the leading
causes of hospital readmissions and associated co-morbidities. Older people [10], patients with
multiple comorbidities, polypharmacy, renal impairment, heart failure, and HIV/AIDS [11] are at
particular risk. One in eight older patients are re-hospitalized because of an ADR within 12 months of
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discharge [12]. One in four individuals over 65 years may experience an ADR during hospitalization
and one third are classified as severe. However, clinical outcomes associated with ADRs are poorly
described [13]. In addition to the direct and indirect costs of care, ADRs reduce patients’ quality of life
and wellbeing [14]. The inability to distinguish between ADRs and patients’ underlying diseases can
result in further prescriptions, multi-medication, and enhanced risks of drug–drug and drug–disease
interactions [15,16]. In European countries, the median percentage of hospital admissions due to an
ADR has been reported as 3.5% and the median percentage of patients who experience an ADR during
hospitalization is 10.1%. This high prevalence of ADRs in European hospital settings inevitably leads
to prolonged hospitalization [17].
The safety of medicines cannot be fully established until they are prescribed to patients and
related reactions come under surveillance through well-established pharmacovigilance systems [18].
As a global campaign, the World Health Organization (WHO) 3rd Global Patient Safety Challenge on
Medication Safety calls for the development and examination of strategies for addressing concerns
regarding medicines’ harms due to medication errors and insufficient monitoring. Since 1971,
the international system for monitoring ADRs using information derived from member states has been
established under the supervision of the WHO, and the operational responsibility remains with the
WHO’s Collaborating Centre for International Drug Monitoring, Uppsala Monitoring Centre, (UMC)
in Sweden. Countries with previously established national systems for spontaneous ADR reporting
agreed to contribute data based on a common reporting form, guidelines, and classifications. Currently,
the ADR database in Uppsala contains several million reports of suspected ADRs [19]. Innovative
strategies should be developed to meet current challenges in medication safety [5,20]. For example,
a thorough description and reporting of ADRs can help with the development of interventions for the
improvement of medicines management [21].
ADR Reporting and Handling in the Norwegian Healthcare System
In Norway, ADRs are estimated to be responsible for 5–10% of all acute internal medicine
hospitalizations and cause approximately 1000 deaths per year [22]. Pharmacovigilance and ADR
reporting have been defined in Norwegian legislation: pharmaceutical companies, doctors, and dentists
are obligated to report on severe or unexpected ADRs [23]. Additionally, other healthcare staff and
patients are recommended to spontaneously report ADRs [24]. The Norwegian Medicines Agency
(NoMA) has the overall responsibility for pharmacovigilance based on the national ADR reporting
system and a database to report ADR data to international databases at the WHO and the European
Medicines Agency (EMA) [24]. A national network consisting of four regional medicines information
and pharmacovigilance centers (RELIS) handles and assesses ADR reports submitted by healthcare
professionals [25]. An annual report is published by NoMA and RELIS: for example in 2018, 5623 ADRs
were reported (1.06 ADRs reports per 1000 inhabitants), of which 3% had a fatal outcome [26].
The number of reports increased by 51% from 2017 due to changes in the regulations for reporting ADRs
by the pharmaceutical industry, which is now obligated to report all ADRs [26]. However, spontaneous
ADR reporting by patients and healthcare staff relies entirely on an individual’s motivation and
consequently a significant level of under-reporting remains in the healthcare system [27]. There is little
integrative and collective knowledge on ADR reporting and monitoring in the Norwegian healthcare
system. Therefore, this systematic review aims to investigate the current trends in ADR reporting,
monitoring, and handling in the Norwegian healthcare system and describe related interventions.
2. Materials and Methods
2.1. Design of the Study
A systematic review was undertaken to ensure the comprehensive coverage of the literature
and integrate current knowledge [28–30] on ADR reporting and monitoring in the Norwegian
healthcare system.
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2.2. Search Strategy and Data Collection
A pilot search in national and international databases identified appropriate keywords for the
search. Next, the Boolean search method was used to retrieve articles describing the condition of ADR
reporting and handling in Norway as follows: “Drug-related side effects and adverse reactions” OR
“adverse drug event” OR “adverse drug reaction” OR “drug side effects” OR “drug toxicity” OR “side
effects of drugs” OR “toxicity, drug” OR “medication side effect” AND Norway OR Norwegian. These
keywords were translated to Norwegian and were used for a similar search process in Norwegian
research databases.
Scientific articles published between 2010 and 2019 in journals in both English and Norwegian
languages were retrieved from the online databases of PubMed [including Medline], Embase, Cinahl,
Web of Science, Cochrane, Norat, Idunn, and SweMed. Inclusion criteria were a precise focus on ADRs
in the Norwegian medicines management context and published in scientific peer-reviewed journals.
2.3. Progression of Systematic Review and Quality of Studies
The authors (MV, HS) performed the systematic review steps independently, but held frequent
discussions for sharing results of their search and agreed further review steps. This led to retrieval of
6559 articles (Table 1).
Table 1. The search strategy and results of different phases of the study (2010–2019).
Databases Total in EachDatabase Title Selection
Abstract
Selection
Full-Text
Appraisal
PubMed [including
Medline] 5703 18 2 2
Scopus 85 15 1 1
Embase 27 5 0 0
Cinahl 196 0 0 0
Web of Science 250 7 1 0
Cochrane 46 3 0 0
Norat 68 26 8 3
Idunn 81 4 0 0
SweMed 103 59 10 0
Manual search/backtracking
references - - - 0
Total 6559 137 22 6
Title readings and deletion of duplicates resulted in 137 articles that were shared between the
authors for further consideration and bilateral agreement in terms of suitability for inclusion in the next
review step. The articles’ abstracts were read by each author (MV, HS) independently and those articles
with a possibility of discussion on ADRs in the Norwegian medicines management context were
selected (n = 22). Their full texts were obtained from the Norwegian and UK libraries and underwent
a careful assessment to select those with a precise focus on the study topic (n = 6). For example,
articles with a focus on medication process, quality improvement, multidisciplinary interventions,
and prescription and administration of drugs rather than ADRs reporting, monitoring, and handling
were excluded. Also, the reference lists of the selected studies was searched manually, but no more
articles were identified. Therefore, the number of articles was reduced to six for further evaluation and
appraisal with respect to methodological transparency and soundness based on the Enhancing the
QUAlity and Transparency of health Research (EQUATOR) tools [31]. The systematic review process
is presented using the preferred reporting items for systematic reviews and meta-analysis (PRISMA)
statement [32] (Figure 1). The characteristics of the articles selected for inclusion in this review are
presented in Table 2.
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Figure 1. The study selection flow diagram according to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) flow diagram.
3. Results
3.1. General Description of the Studies
Of the selected studies, one was conducted in the Netherlands with the inclusion of data from
Norway [33] and the remainder were undertaken in Norway [34–38]. Three articles [34,36,37] were
in the Norwegian language and the rest [33,35,38] were published in English. They all used a
cross-sectional descriptive design for data collection and analysis. The findings of the selected studies
on ADR reporting and handling in the Norwegian healthcare context were presented under three central
aspects of ‘patient reporting schema’ [33,36], ‘healthcare provider reporting schema’ [33,34,36,37],
and ‘current pharmacovigilance system’ [33,35–38]. e c aracteristics of the studies’ findings were
summarized in Table 3
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Table 2. List of studies selected for data analysis and synthesis in this systematic review.
Title Authors Year Country Aim Methods
Experiences with adverse drug
reaction reporting by patients:
an 11-country survey.
van
Hunsel et
al. [33]
2012
Netherlands with the
inclusion of data from
Norway
To review the methods of patient
reporting of adverse drug reactions
(ADRs) in 11 countries and to compare
different aspects of their experiences
aimed at describing current practice.
A survey based on telephone interviews,
e-mail discussions, and field visits.
Bivirkninger av plantebaserte
produkter
Nergård
[34] 2013 Norway
To describe the reports of ADRs of
plant-based products in Norway from
2003–2012.
A retrospective cross-sectional study of
reported ADRs from plant-based
products in Norway 2003–2012.
Joint medicine-information and
pharmacovigilance services could
improve detection and
communication about
drug-safety problems
Schjøtt &
Bergman
[35]
2014 Norway
To describe the potential of the RELIS’s
dual service to improve detection and
communication of drug-safety problems.
Searching the RELIS database for
question-answer pairs about ADRs using
the Norwegian ADRs database.
Patient reporting of adverse drug
reactions in Norway 2010–2013
Fjermeros
et al. [36] 2015 Norway
To review patients’ reports of ADRs to
the Norwegian Medicines Agency since
1 March 2010.
A cross-sectional retrospective study of
ADRs reporting of patients to the
Norwegian Medicines Agency (NoMA).
Bivirkninger ved bruk av
antikoagulasjonsmidler i 2013-15
(Anticoagulant-associated
adverse drug reactions in
2013–2015)
Eek et al.
[37] 2018 Norway
To obtain a better insight into the ADRs
profiles of the new direct-acting oral
anticoagulants (DOACs).
A retrospective cross-sectional study of
registry data (RELIS database of ADRs
and the Norwegian Prescription
Database (NorPD)).
Adverse drug reaction reporting:
how can drug consumption
information add to analyses
using spontaneous reports?
Svendsen
et al. [38] 2018 Norway
To combine ADRs reports with drug
consumption data to demonstrate the
additional information.
Combining all Norwegian ADR reports
2004–2013 from the EudraVigilance
database (n = 14.028) with dispensing
data from the Norwegian Prescription
Database (more than 800 million
dispensed prescriptions during
2004–2013).
.
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Table 3. Characteristics of the studies’ findings on Adverse Drug Reactions (ADRs) reporting and monitoring.
Studies/
Characteristics Number of Reports
Size of
Population
Covered
Type of
Reporting Age of Patients
Gender of
Patients
Most Commonly
Reported Events
Patient
Reporting
Healthcare
Provider
Reporting
Pharmacovigilance
System
van Hunsel et
al. [33]
30 consumer reports per
month (14% of total) No data Electronic No data No data
Only on registered
drugs
Sophisticated
system without
follow up
Causality
assessment and
personal feedback
Reporting only
serious events
Nergård [34]
260 reports associated
with plant-based
products from 2003–2012
No data No data
Average age of 52
years; 20% of the
sample was >70 years
72% female
Hypersensitivity
reactions (27%),
hepatic events (20%),
and interactions with
anticoagulants (8%)
Not relevant, only
reports from
healthcare
providers
included
No data RELIS database
Schjøtt &
Bergman [35]
5427 (26%) of 21,071
question-answer pairs,
and 791 (4%) of a total of
22,090 reports in the
Norwegian ADR
database
No data Electronic No data No data
Dose escalation,
craving, and
withdrawal reactions
to Lyrica®
(pregabalin)
No data
Provision of
feedback by
pharmacists and
clinical
pharmacologists
to healthcare
professionals
Norwegian ADR
database and the
RELIS database
Fjermeros et
al. [36]
755 reports from patients
and 9629 reports from
healthcare staff in the
time period of March
2010–December 2013
No data No data
Average age not
given. The patients
most commonly
reporting were in the
age range of 20–29
years (29%), whereas
healthcare providers’
reports most
frequently concerned
those aged 0–9 years
(17%)
63% female
among the
patient
reports, 58%
female among
the healthcare
staff reports
Adverse mental and
neurological reactions
were commonly
reported by patients,
while healthcare
providers reported
mostly on general
symptoms and local
reactions.
No data No data Norwegian ADRdatabase (NoMA)
Eek et al. [37]
409 reports on ADRs
associated with
anticoagulants in the
time period of June
2013–May 2015
Approximately
145,000
anti-coagulant
users
No data Average age was75–80 years 44% female
Cerebral
haemorrhage,
haemorrhage in
skin/muscle/joint/mucous
membranes and
gastrointestinal
haemorrhage
Not relevant, only
reports from
healthcare
providers
included
No data
Norwegian ADRs
database (NoMA)
and RELIS
database
Svendsen et al.
[38]
14.028 from the
EudraVigilance database
and 800 million from the
Norwegian Prescription
Database
Data from 5.1
million
different
persons.
Electronic No data
22,351 female
and 39,391
male users of
methylphenidate
Physical and
psychological
symptoms in both
males and females
No data No data
EudraVigilance
database,
Norwegian
prescription
database
ADR: Adverse drug reaction.
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3.2. Patient Reporting Schema
The introduction of ADR reporting in Norway by patients was started relatively late in 2010.
Only an electronic form was available, and this did not accept reports on unregistered products.
This electronic reporting form was very sophisticated and was characterized by completeness checks,
data importation directly to a database, presence of free-text and mandatory spaces in the form,
and a drop-down list for the selection of co-medication. However, no drop-down lists to select
ADRs were included and there was no opportunity for follow-up with patients regarding their ADR
reports [33]. In the review and analysis of all ADR reports submitted to NoMA by patients from
2010 to 2013 (n = 755), female patients reported ADRs in 63% of cases and were most commonly in
the age range of 20–29 years (29%) or 30–39 years (23%). Analgesics, including tramadol, codeine,
diclofenac, and ibuprofen, were the most commonly mentioned drug group in the ADR reports. There
were 1.1 psychotropic drugs per ADR report, and adverse mental and neurological reactions, such as
dizziness, anxiety, depression, insomnia, and suicidal thoughts, were the most common suspected
adverse reactions reported [36].
3.3. Healthcare Provider Reporting Schema
In regional centers in Norway only reports from healthcare professionals were assessed for
causality, with personalized feedback provided [33]. In the review and analysis of all ADR reports
submitted to NoMA by healthcare providers from 2010–2013 (n = 9629), 58% of healthcare personnel
reports were for female patients, most frequently in the age group 0–9 years (17%) and 60–69 years
(13%). The number of suspected drugs per ADR report was 1.4, and the most frequently mentioned
drug group in the ADR reports was vaccines, where non-specific symptoms and local reactions were
the typical suspected adverse reactions [36]. 291 reports were submitted to RELIS by healthcare
providers from 2013–2015 (n = 409) on oral anticoagulants, including warfarin, dabigatran, rivaroxaban,
and apixaban. Rivaroxaban had the highest number of reports (6.5 reports per 1000 anticoagulant
users). The patients were mainly older than 70 years of age (76%); 91 patients experienced cerebral
haemorrhages, blood clots, cognitive impairment, headache, and hair loss. The highest number
of fatal outcomes were related to rivaroxaban (1.1 deaths/1000 users). Comorbidities, older age,
and polypharmacy contributed to increased seriousness of side effects and patient death [37].
The study of ADR reporting by healthcare professionals on plant-based products including herbal
dietary supplements and plant-based drugs e.g., Hypericum perforatum, Ginko biloba, and Valeriana,
in the period 2003–2012 showed 260 submitted ADR reports to RELIS, of which 250 reports were related
to herbal dietary supplements. There were 10 reports on plant-based drugs, all reported by pharmacists.
Overall, doctors most frequently reported ADRs to the RELIS (n= 196, 75%). Severe ADRs were
reported in 42% of cases including hypersensitivity (n = 71), hepatic damage (n = 56), and interactions
with anticoagulant drugs (n = 20). Also, 72% and 20% of the reports specified to 53 years old women
and patients with the age ≥70 years [34].
3.4. The Current Pharmacovigilance System
Norway shared only reports classified as serious with the EudraVigilance database. The electronic
report was imported into the database, thereby saving the organization time and ensuring data
completeness and facilitating assessment. Also, the financial burden of human resources influenced
the decision by the Norwegian Medicines Agency on prioritization and time allocation for handling
individual reports. No medical confirmation of the patient reports was made, but patients could
contact the Norwegian Medicines Agency to actively follow-up their information. It was impossible to
share patients’ reports with the primary healthcare provider [33]. The spontaneous reporting system
by healthcare providers could not be used to compare the incidence of ADRs associated with different
medicines within the same class [37]. ADR reports from patients were more varied than those from
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healthcare providers. Overall, spontaneous patient ADR reporting supplemented healthcare providers
ADR reporting [36].
ADR reports from 2004–2013 from the EudraVigilance database (n = 14,028) were combined with
dispensing data (n = 800 million) from the Norwegian Prescription Database. Dividing report numbers
for each prescribed medicine with the number of users was used to calculate the medicine-specific
consumption-adjusted ADR rates to identify medicines with higher risks of safety issues. A high number
of ADR reports involved diclofenac, olanzapine, diazepam, warfarin, sildenafil, and methylphenidate.
The increased ADR reports and the medicine-specific consumption-adjusted ADR rate for atorvastatin
in 2010 reflected a true increase in the number of reports rather than the number of users: 27 different
ADRs, with at least one instance, were reported. These included dizziness, nausea, diarrhoea,
feeling abnormal, and anxiety in women and aggression, self-injurious behaviors, cerebral infarction,
palpitations, attention deficit hyperactivity disorder, hypertension, and vomiting in men. Many of
the most commonly used drugs had more than 500,000 users and less than 100 ADR reports; this was
due to either underreporting or rarity of serious ADRs. 78% of all ADRs were reported within seven
days [38].
The RELIS database, as the network of four regional medicine-information and pharmacovigilance
centers where pharmacists asked questions and provided feedback to healthcare professionals regarding
drug-related questions and ADRs, along with and the Norwegian ADR database (as a reference) were
searched in the time period 2003–2012. Lyrica(R) (pregabalin) and drug abuse after its marketing in
Norway in September 2004 was selected to assess its safety-related reports. Accordingly, 5427 (26%) of
21,071 parallel questions and answers between pharmacists and healthcare providers in the RELIS
database concerned ADRs, which were considered references in 4% of reports in the Norwegian ADRs
database. On the other hand, the Norwegian ADRs database was used as a reference in 7% of parallel
questions and answers regarding ADRs. Eleven questions and 13 ADR reports concerned Lyrica(R) and
different aspects of its abuse: reports described dose escalation problems, craving, and withdrawal
reactions, which led to the detection of new drug-safety problems [35].
4. Discussion
This review has described the various methods used for reporting, monitoring, and handling
ADRs in the Norwegian healthcare system. In general, emphasis was placed on the role of patients,
healthcare providers, and innovative systems for ADRs reporting and monitoring.
4.1. Patients vs. Healthcare Providers’ Reporting of ADRs
The study findings demonstrated how patients could be involved in ADR reporting and the
barriers to patients’ participation in terms of their knowledge, active involvement and participation
in medicines management, and feedback on reports. Rather, there was an emphasis on the extent of
healthcare providers’ collaboration with the reporting of ADRs along with the use of their knowledge
and expertise for the active monitoring of ADRs and medicines adverse side effects. Since low reporting
rates of ADRs contribute to major delays in the identification of medicines management issues [18],
patients’ reports have potential to improve the comprehensiveness of data collection by healthcare
providers, as needed for any pharmacovigilance system. Comparisons between reports by patients and
those by healthcare providers mostly highlight different points of view that can enrich spontaneous
reporting data [39–41]. Variations in reporting processes and inclusion criteria for schemes and
report types are responsible for differences between patients’ and healthcare providers’ reports [42].
Patients often reported more suspected ADRs to more medicines than did healthcare professionals,
who often focused on patient-related information such as weight and height. Healthcare professionals
usually reported the more serious reactions that lead to hospitalization, life threatening conditions,
or death [43–45].
It has been reported that patients may not be aware of ADR reporting systems and may be
confused about how and where to report. While patients are encouraged to report known ADRs
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to prevent similar suffering in other patients, they need to increase their familiarity with reporting
processes to improve the quality and quantity of reporting [46]. To improve patients’ attitudes
toward the reporting of ADRs, there is a need to increase public awareness campaigns to address the
importance of reporting. By providing feedback to patients with regard to their reporting, as well as
involving patients in decision making based on the results of reports, patient awareness should be
increased [47]. One strategy could be to design a single official reporting system for both patients
and healthcare providers, and measures should be taken to improve the interfacing of patients’ and
healthcare providers’ reports to handle the potential increase in the number of reports [48]. In addition,
all healthcare providers, including nurses who spend the most time with patients and collect most
data on patients’ bedside conditions, should be educated on how to participate in reporting ADRs as
only multiple reports can improve the impact of the pharmacovigilance system [3,4,20,49,50].
4.2. The Need for ADR Profiles for Identifying, Documenting and Reporting ADRs
The study findings showed the use of innovative methods and data collection methods for
providing a comprehensive picture of ADRs in the Norwegian healthcare context. Some barriers
to the effective implementation of the ADR reporting and monitoring system could be financial
constraints, absence of clinical confirmation of patients’ reports, impossibility of sharing patients’
reports with primary healthcare providers, and inability to compare reports from different sources.
The development and implementation of protocols for ADR monitoring as an efficient intervention to
improve medicines management can contribute to lower reporting costs. Mechanisms for reporting
and recording ADRs should not only provide information about the total number of reports, but also
their severity, unexpectedness, and the degree of causality attributed to ADRs [51]. Variabilities in data
fields used to report ADRs hinder the comparability of collected data from different reporting systems.
Therefore, a common standardized dataset characterized by quality, comparability, and reporting rates
can optimize drug safety surveillance efforts [52]. Moreover, regulation at the system level needs the
inclusion of comprehensive, systematic, and regular patient checking for undesirable adverse effects
of medicines. In this respect, the Adverse Drug Reaction (ADRe) profile, led by nurses, with the
involvement of the multidisciplinary team, provides a suitable tool to achieve improved patient
care and increased understanding of the impact of ADRs [3]. Modern electronic health records
systems can assist healthcare professionals with completing ADR reporting. They are characterized
by being easily accessible on the web and offer the possibility of sending emails or including direct
hyperlinks to healthcare professionals’ desktops [18]. For instance, spontaneous ADR reporting is
a pharmacovigilance method in Canada supervised by the Canadian Vigilance Program at Health
Canada. ADR reports submitted to the system are sent by post, telephone, or via the internet, and are
used to detect medication safety alerts [53]. Such systems also enable collecting ADRs reports from
patients at their own homes, which is particularly important for those who live in remote areas, to allow
direct contact with healthcare providers based in urban areas [17,54].
5. Conclusions
The results of this systematic review have described initiatives for ADR reporting, monitoring,
and handling in the Norwegian healthcare system. The results emphasize the need for data collection
systems to provide a comprehensive picture of ADRs. ADR reporting could be improved by: facilitating
patients’ participation in reporting ADRs, and sending them feedback on their reports; sharing reports
with primary healthcare providers, to enhance healthcare providers’ active collaboration with ADR
reporting; implementing existing ADRe profiles for interactive reporting between patients, nurses
and healthcare providers [3,4]; assessing reports in terms of quality and impact on the patient and the
healthcare system, and facilitating access to reporting systems in inpatient and outpatient settings.
More studies also are needed to find how ADRe pharmacovigilance profiles can improve the safety of
medicines management in Norway.
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